Skip to main content
Premium Trial:

Request an Annual Quote

Cepheid Gets Canadian OK for MRSA/SA Test

NEW YORK (GenomeWeb News) – Cepheid has received marketing clearance in Canada for its Xpert MRSA/SA Blood Culture test for rapid detection of methicillin-resistant Staphylococcus aureus and Staphylococcus aureus in blood culture bottles showing gram-positive cocci.

The test processes positive blood culture specimens to determine if a patient's blood is infected with MRSA or SA, which Cepheid said are frequent causes of sepsis in hospitalized patients. Such a test can enable physicians to "quickly de-escalate from broad-spectrum antibiotic treatment to a more effective targeted therapy, thus reducing risk of resistance and improving patient outcomes," the firm said in a statement today.

According to Cepheid, more than 250,000 Canadian patients experience infected surgical wounds, blood infections, and antibiotic-resistant organisms while in the hospital each year.

Cepheid noted that the Xpert MRSA/SA Blood Culture test is the firm's sixth test to receive a license from Health Canada.

The Scan

mRNA-Based Vaccine on the Way in China

China may soon have its own mRNA-based vaccine, according to Nature News.

Arranged Killing, Fraud Alleged by Prosecutors

The Wall Street Journal reports that prosecutors allege that the co-founder of a biotech arranged to have a business associate who threatened to expose him as a fraud killed.

Whirlwind Decade of CRISPR

The New York Times looks back at the 10 years since the University of California, Berkeley's Jennifer Doudna and her colleagues published their CRISPR paper.

PNAS Papers on Blue Cone Monochromacy Structural Variants, HIV-1 Mutant, T-ALL

In PNAS this week: structural variants linked to blue cone monochromacy, HIV-1 variants affecting the matrix protein p17, and more.